RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Cause, conseguenze, e aspetti terapeutici dell'iperomocisteinemia nell'uremia e nel diabete.
• 2 - PEROSSIDAZIONE LIPIDICA, ATTIVAZIONE PIASTRINICA ED INFIAMMAZIONE ASSOCIATI A RIDOTTI LIVELLI DI LIPOPROTEINE AD ALTA DENSITA' (HDL)
• 3 - Effetti clinici e molecolari dell'eccesso di glucocorticoidi
• 4 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 5 - Iperlipidemia, Aterosclerosi e Insufficienza Renale
• 6 - RUOLO DEI MECCANISMI DI SEGNALE CELLULARE E DELLE SPECIE REATTIVE DELL'OSSIGENO E DELL'AZOTO NELL'INVECCHIAMENTO CELLULARE E NELLA CRESCITA NEOPLASTICA.
• 7 - Meccanismi cellulari e molecolari del danno arterioso nel paziente ad alto rischio cardiovascolare
• 8 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 9 - Nefrolitiasi calcica e ostepatie associate: studio delle interazioni tra cause genetiche e nutrizionali e dei meccanismi patogenetici.
• 10 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA CLINICA
  • NEFROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
    • THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Classificazione geografica

• Regione: Puglia

Bibliografia

1.Stenvinkel P et al. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial; 15:329, 2002.
2. London G et al. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int; 51:1678,1997.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med; 340: 115-26, 1999.
4. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation; 100: 1148-50, 1999.
5. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med; 290: 697-701, 1974.
6. Koenig W et al. CRP, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg Cohort Study. Circulation; 99: 237, 1999.
7. Ridker P et al. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lp(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA; 285: 2481, 2001.
8. Ridker P et al. Comparison of C-Reactive Protein and Low-Density Lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med; 347:1557, 2002.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation; 105: 1135- 43, 2002.
10. Hunt JL, et al. Bone formation in carotid plaques: A clinicopathological study. Stroke 33: 1214–1219, 2002
11. Guérin AP, et al. Arterial stiffening and vascular calcifications in end-stage renal disease Nephrol Dial Transplant; 15:1014-1021, 2000.
12. Goodman WG, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 2000;342:1478-1483.
13. Raggi P, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695–701, 2002.
14. Amann K, et al. Hyperphosphatemia - a silent killer of patients with renal failure? Nephrol Dial Transplant 14: 2085,2087 1999.
15. Giachelli CM. Vascular Calcification Mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004.
16. Jakoby MG et al. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 9: 11–15, 2000.
17. Davies MR, et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol in press, 2005.
18. Musgrave DS, et al. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 24: 541-547, 1999.
19. Dhore CR, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21(12): 1998-2003, 2001.
20. Zeisberg M, et al. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol Dial Transplant 19: 759-761, 2004.
21. Kaden JJ, et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 13:560-566, 2004.
22. Boström K, et al. Bone morphogenetic protein expression in human and atherosclerotic lesions. J Clin Invest 91: 1800-1809, 1993.
23. Willette RN, et al. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 36: 120-125, 1999.
24. Schluesener HJ, et al. Immunolocalization of BMP-6, a novel TGF-beta-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis 113:153-156, 1995.
25. Davies MR, et al. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14: 1559-1567, 2003.
26. Vukicevic S, et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102:202-214, 2002.
27. Dorai H, et al. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184(1):37-45, 2000.
28. Stenvinkel P, et al. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15: 329-337, 2002.
29. Pertosa G, et al. Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 54: 570-579, 1998..
30. Memoli B, et al. In vivo modulation of soluble “antagonistic” IL-6 receptor synthesis and release in end stage renal disease. J Am Soc Nephrol 16:1099-1107, 2005.
31. Ketteler M, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361: 827–833, 2003.
32. Moe SM, et al. Fetuin-A and Matrix Gla protein are important inhibitors of vascular calcification in CKD. J Am Soc Nephrol 14: 692A, 2003.
33. Szweras M, et al. Alpha 2-HS Glycoprotein/Fetuin, a transforming growth factor-β/Bone Morphogenetic Protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 277:19991-19997, 2002.
34. Behrendt D, Ganz P: Endothelial function: from vascular biology to clinical applications. Am J Cardiol 90 (Suppl): 40L-48L, 2002.
35. Nakayama M, Yamada K, Yamamoto Y, et al: Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 42: 117-120, 1994.
36. Gris J-C, Branger B, Velina F, et al: Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 46: 807-813, 1994.
37. Lottermoser K, Petras S, Poge U, et al: The fibrinolytic system in chronic renal failure. Eur J Med Res 6 (9): 372-376, 2001.
38. Kari JA, Donald AE, Vallance DT, et al: Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 52: 468-472, 1997.
39. Kojda G, Harrison D: Interactions between NO and reactive species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovascular Research 43:562-571, 1999.
40. Beckman JS, Koppenol WH: Nitric oxide, super-oxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-1437, 1996
41. Vallance P, Leone A, Calver A, et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
42. Bonomini M, Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Consoli A, Amoroso L, Gizzi F, De Lutiis AM, Felaco M. Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney International 2005, in press
43. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HB, Jr. Lecithin Cholesterol Acyltransferase Deficiency and Fish Eye Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), The Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill. 2001: 2817-2833
44. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J.Lipid Res. 1997; 38:191-205
45. Ayyobi AF, McGladdery SH, Chan S, Mancini GBJ, Hill JS and Frohlich JJ. Lecithin-cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 177: 361-366, 2004.
46. Mehlum A, Gjernes E, Solberg LA, Hagve TA, Prydz H.Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis. APMIS 108:336-42, 2000.
47. Zhu X, Herzenberg AM, Eskandarian M, Maguire GF, Scholey JW, Connelly PW, Ng DS.A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy.
Am J Pathol. 165:1269-78, 2004

Parole Chiave

INSUFFICENZA RENALE CRONICA; LCAT; INSULINO RESISTENZA; DANNO ENDOTELIALE; CALCIFICAZIONI VASCOLARI; BMP-7; INFIAMMAZIONE; ATEROGENESI; RISCHIO CARDIOVASCOLARE